var data={"title":"Daunorubicin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Daunorubicin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5982?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=daunorubicin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Daunorubicin: Patient drug information&quot;</a> and <a href=\"topic.htm?path=daunorubicin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Daunorubicin: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708684\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Extravasation:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-4em;margin-left:4em;\">Daunorubicin must be given into a rapidly flowing intravenous infusion. It must never be given by the intramuscular or subcutaneous route. Severe local tissue necrosis will occur if there is extravasation during administration.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Experienced physician: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">It is recommended that daunorubicin be administered only by physicians who are experienced in leukemia chemotherapy and in facilities with laboratory and supportive resources adequate to monitor drug tolerance and protect and maintain a patient compromised by drug toxicity.The physician and institution must be capable of responding rapidly and completely to severe hemorrhagic conditions and/or overwhelming infection.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Bone marrow suppression: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Severe myelosuppression occurs when used in therapeutic doses; this may lead to infection or hemorrhage.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Myocardial toxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Myocardial toxicity manifested in its most severe form by potentially fatal congestive heart failure may occur either during therapy or months to years after termination of therapy. The incidence of myocardial toxicity increases after a total cumulative dose exceeding 400 to 550 mg/m<sup>2</sup> in adults, 300 mg/m<sup>2</sup> in children older than 2 years of age, or 10 mg/kg in children younger than 2 years of age. </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hepatic impairment:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Dosage should be reduced in patients with impaired hepatic function.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Renal impairment:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Dosage should be reduced in patients with impaired renal function.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157118\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Cerubidine;</li>\n      <li>Daunorubicin Hydrochloride for Injection</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157160\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Anthracycline;</li>\n      <li>\n        Antineoplastic Agent, Topoisomerase II Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157121\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">Daunorubicin is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting (Hesketh 2017; Roila 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Manufacturer&rsquo;s labeling:</i></b> <b>Note:</b> Cumulative doses above 550 mg/m<sup>2</sup> in adults without risk factors for cardiotoxicity and above 400 mg/m<sup>2</sup> in adults receiving chest irradiation are associated with an increased risk of cardiomyopathy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute lymphocytic leukemia (ALL):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 45 mg/m<sup>2</sup> on days 1, 2, and 3 (in combination with vincristine, prednisone, and asparaginase)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute myeloid leukemia (AML):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults &lt;60 years: Induction: IV: 45 mg/m<sup>2</sup> on days 1, 2, and 3 of the first course of induction therapy; subsequent courses: 45 mg/m<sup>2</sup> on days 1 and 2 (in combination with cytarabine)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults &ge;60 years: Induction: IV: 30 mg/m<sup>2</sup> on days 1, 2, and 3 of the first course of induction therapy; subsequent courses: 30 mg/m<sup>2</sup> on days 1 and 2 (in combination with cytarabine)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>\n        <i>Indication-specific dosing (off-label dosing):</i></b></p>\n    <p style=\"text-indent:0em;margin-left:2em;\">\n      <b>ALL:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>CALGB 8811 regimen:</i> IV: 45 mg/m<sup>2</sup> (in patients &lt;60 years) or 30 mg/m<sup>2</sup> (in patients &ge;60 years) on days 1, 2, and 3 of induction (Course I; 4 week cycle), in combination with cyclophosphamide, prednisone, vincristine, and asparaginase (Larson, 1995)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>CCG 1961:</i> Adults &le;21 years: IV: Induction: 25 mg/m<sup>2</sup> once weekly for 4 weeks (in combination with vincristine, prednisone, and asparaginase) (Nachman 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>GRAALL-2003:</i> Adults &le;60 years: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Induction: 50 mg/m<sup>2</sup> on days 1, 2, and 3 <b>and</b> 30 mg/m<sup>2</sup> on days 15 and 16 (in combination with prednisone, vincristine, asparaginase, cyclophosphamide, and G-CSF support) (Huguet 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Late intensification: 30 mg/m<sup>2</sup> on days 1, 2, and 3 (in combination with prednisone, vincristine, asparaginase, cyclophosphamide, and G-CSF support) (Huguet 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>MRC UKALLXII/ECOG E2993:</i> Adults &lt;60 years: IV: Induction (Phase I): 60 mg/m<sup>2</sup> on days 1, 8, 15, and 22 (in combination with vincristine, asparaginase, and prednisone) (Rowe 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>PETHEMA ALL-96:</i> Adults &le;30 years: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Induction: 30 mg/m<sup>2</sup> on days 1, 8, 15, and 22 (in combination with vincristine, prednisone, asparaginase, and cyclophosphamide) (Ribera 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Consolidation-2/Reinduction: 30 mg/m<sup>2</sup> on days 1, 2, 8, and 9 (in combination with vincristine, dexamethasone, asparaginase, and cyclophosphamide) (Ribera 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Protocol 8707:</i> Adults &le;60 years: IV: Induction and Consolidation 2A cycles: 60 mg/m<sup>2</sup> on days 1, 2, and 3 (in combination with vincristine, prednisone, and asparaginase). An additional 60 mg/m<sup>2</sup> daunorubicin dose may be administered on day 15 of induction if bone marrow biopsy on day 14 shows residual disease (Linker 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>AML:</b> Induction:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>CCG 2891:</i> Adults &lt;21 years: IV: 20 mg/m<sup>2</sup>/day continuous infusion on days 0 to 4 and 10 to 14 (in combination with dexamethasone, cytarabine, thioguanine, and etoposide) (Woods 1996)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults &lt;60 years: IV: 90 mg/m<sup>2</sup> on days 1, 2, and 3 (in combination with cytarabine). If residual disease was observed on day 12 to day 14 bone marrow biopsy, 45 mg/m<sup>2</sup> for 3 days was administered (in combination with cytarabine) (Fernandez 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults &lt;60 years: IV: 60 mg/m<sup>2</sup> on days 1, 2, and 3 (in combination with cytarabine and cladribine); may repeat if partial remission occurs (Holowiecki 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults &ge;60 years: IV: 45 or 90 mg/m<sup>2</sup> on days 1, 2, and 3 (in combination with cytarabine); the escalated 90 mg/m<sup>2</sup> dose was associated with increased remission rates and overall survival in the subgroup of patients 60 to 65 years of age as compared to patients &gt;65 years (Lowenberg 2009)</p>\n    <p style=\"text-indent:2em;\">\n      <b>Acute promyelocytic leukemia (APL):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Induction: Adults: IV: 50 mg/m<sup>2</sup> on days 3, 4, 5, and 6 (in combination with ATRA and cytarabine) (Powell, 2010) <b>or</b> 60 mg/m<sup>2</sup> on days 1, 2, and 3 (in combination with ATRA and cytarabine) (Ades 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Consolidation: Adults: IV: 50 mg/m<sup>2</sup> on days 1, 2, and 3 for 2 cycles (in combination with ATRA; arsenic trioxide was administered for 2 cycles prior to daunorubicin and ATRA) (Powell, 2010) <b>or</b> 60 mg/m<sup>2</sup> on days 1, 2, and 3 during cycle 1 of consolidation (in combination with cytarabine), followed by 45 mg/m<sup>2</sup> on days 1, 2, and 3 during cycle 2 of consolidation (in combination with cytarabine) (Ades 2008)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157142\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=daunorubicin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Daunorubicin: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Daunorubicin is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting (Dupuis 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Manufacturer&rsquo;s labeling:</i></b> <b>Note:</b> Cumulative doses above 300 mg/m<sup>2</sup> in children &gt;2 years or 10 mg/kg in children &lt;2 years of age are associated with an increased risk of cardiomyopathy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute lymphocytic leukemia (ALL):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &lt;2 years or BSA &lt;0.5 m<sup>2</sup>: Remission induction: IV: 1 mg/kg/dose on day 1 every week for up to 4 to 6 cycles (in combination with vincristine and prednisone)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;2 years and BSA &ge;0.5 m<sup>2</sup>: Remission induction: IV: 25 mg/m<sup>2</sup> on day 1 every week for up to 4 to 6 cycles (in combination with vincristine and prednisone)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>\n        <i>Indication-specific dosing (off-label dosing):</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>ALL:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>CCG 1961:</i> Children &ge;10 years and Adolescents: IV: Induction: 25 mg/m<sup>2</sup> once weekly for 4 weeks (in combination with vincristine, prednisone, and asparaginase) (Nachman 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>GRAALL-2003:</i> Adolescents &ge;15 years: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Induction: 50 mg/m<sup>2</sup> on days 1, 2, and 3 <b>and</b> 30 mg/m<sup>2</sup> on days 15 and 16 (in combination with prednisone, vincristine, asparaginase, cyclophosphamide, and G-CSF support) (Huguet 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Late intensification: 30 mg/m<sup>2</sup> on days 1, 2, and 3 (in combination with prednisone, vincristine, asparaginase, cyclophosphamide, and G-CSF support) (Huguet 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>MRC UKALLXII/ECOG E2993: </i>Adolescents &ge;15 years: IV: Induction (Phase I): 60 mg/m<sup>2</sup> on days 1, 8, 15, and 22 (in combination with vincristine, asparaginase, and prednisone) (Rowe 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>PETHEMA ALL-96:</i> Adolescents &ge;15 years: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Induction: 30 mg/m<sup>2</sup> on days 1, 8, 15, and 22 (in combination with vincristine, prednisone, asparaginase, and cyclophosphamide) (Ribera 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Consolidation-2/Reinduction: 30 mg/m<sup>2</sup> on days 1, 2, 8, and 9 (in combination with vincristine, dexamethasone, asparaginase, and cyclophosphamide) (Ribera 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute myeloid leukemia (AML):</b> Induction:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>CCG 2891:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &lt;3 years: IV: 0.67 mg/kg/day continuous infusion on days 0 to 4 and 10 to 14 (in combination with dexamethasone, cytarabine, thioguanine, and etoposide) (Woods 1996)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;3 years and Adolescents: IV: 20 mg/m<sup>2</sup>/day continuous infusion on days 0 to 4 and 10 to 14 (in combination with dexamethasone, cytarabine, thioguanine, and etoposide) (Woods 1996)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>MRC AML 10/12:</i> Children &le;14 years: IV: 50 mg/m<sup>2</sup> on days 1, 3, and 5 for 2 cycles (in combination with cytarabine and etoposide) (Gibson 2005)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157122\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157123\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;display:inline\">The manufacturer's labeling recommends the following adjustment:  S<sub>cr</sub> &gt;3 mg/dL: Administer 50% of normal dose</p>\n    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">The following adjustments have also been recommended (Aronoff, 2007):</p>\n    <p style=\"text-indent:-4em;margin-left:6em;text-align:justify;\">Adults: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-4em;margin-left:6em;text-align:justify;\">Children:</p>\n    <p style=\"text-indent:-4em;margin-left:8em;text-align:justify;\">CrCl &lt;30 mL/minute: Administer 50% of dose</p>\n    <p style=\"text-indent:-4em;margin-left:8em;text-align:justify;\">Hemodialysis/continuous ambulatory peritoneal dialysis (CAPD): Administer 50% of dose</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157124\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;display:inline\">The manufacturer's labeling recommends the following adjustments: </p>\n    <p style=\"text-indent:-4em;margin-left:6em;text-align:justify;\">Serum bilirubin 1.2 to 3 mg/dL: Administer 75% of dose </p>\n    <p style=\"text-indent:-4em;margin-left:6em;text-align:justify;\">Serum bilirubin &gt;3 mg/dL: Administer 50% of dose</p>\n    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">The following adjustments have also been recommended (Floyd, 2006):</p>\n    <p style=\"text-indent:-4em;margin-left:6em;text-align:justify;\">Serum bilirubin 1.2 to 3 mg/dL: Administer 75% of dose</p>\n    <p style=\"text-indent:-4em;margin-left:6em;text-align:justify;\">Serum bilirubin 3.1 to 5 mg/dL: Administer 50% of dose</p>\n    <p style=\"text-indent:-4em;margin-left:6em;text-align:justify;\">Serum bilirubin &gt;5 mg/dL: Avoid use</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157095\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injectable, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg/mL (4 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injectable, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg/mL (4 mL, 10 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157080\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157098\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Daunorubicin is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting (Dupuis 2011; Hesketh 2017; Roila 2016).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">IV: For IV administration only. Do not administer IM or SubQ. Administer as slow IV push over 1 to 5 minutes into the tubing of a rapidly infusing IV solution of D<sub>5</sub>W or NS or may dilute further and infuse over 15 to 30 minutes.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Extravasation management:</b> If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity. Initiate antidote (dexrazoxane or dimethyl sulfate [DMSO]). Apply dry cold compresses for 20 minutes 4 times daily for 1 to 2 days (Perez Fidalgo 2012); withhold cooling beginning 15 minutes before dexrazoxane infusion; continue withholding cooling until 15 minutes after infusion is completed. Topical DMSO should not be administered in combination with dexrazoxane; may lessen dexrazoxane efficacy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Dexrazoxane:</i> Adults: 1000 mg/m<sup>2</sup> (maximum dose: 2000 mg) IV (administer in a large vein remote from site of extravasation) over 1 to 2 hours days 1 and 2, then 500 mg/m<sup>2</sup> (maximum dose: 1000 mg) IV over 1 to 2 hours day 3; begin within 6 hours of extravasation. Day 2 and day 3 doses should be administered at approximately the same time (&plusmn; 3 hours) as the dose on day 1 (Mouridsen 2007; Perez Fidalgo 2012). <b>Note:</b> Reduce dexrazoxane dose by 50% in patients with moderate to severe renal impairment (CrCl &lt;40 mL/minute).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>DMSO:</i> Children and Adults: Apply topically to a region covering twice the affected area every 8 hours for 7 days; begin within 10 minutes of extravasation; do not cover with a dressing (Perez Fidalgo 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49130969\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]).  </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157096\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute lymphocytic leukemia:</b> Treatment (remission induction) of acute lymphocytic leukemia (ALL) in children and adults (in combination with other chemotherapy)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute myeloid leukemia:</b> Treatment (remission induction) of acute myeloid leukemia (AML) in adults (in combination with other chemotherapy)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157169\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">DAUNOrubicin may be confused with DACTINomycin, DAUNOrubicin liposomal, DOXOrubicin, DOXOrubicin liposomal, epiRUBicin, IDArubicin, valrubicin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157087\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Cardiac failure (dose-related, may be delayed for 7 to 8 years after treatment), ECG abnormality (transient, generally asymptomatic and self-limiting; includes atrial premature contractions, ST segment changes on ECG, supraventricular tachycardia, ventricular premature contractions)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Alopecia (reversible)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (mild), stomatitis, vomiting (mild)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Red urine discoloration</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Bone marrow depression (onset: 7 days; nadir: 10 to 14 days; recovery: 21 to 28 days; primarily leukopenia; anemia, thrombocytopenia)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Radiation recall phenomenon</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Discoloration of sweat</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hyperuricemia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain, diarrhea, discoloration of saliva, gastrointestinal ulcer</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Post-injection flare</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Discoloration of tears</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anaphylactoid reaction, cardiac arrhythmia, cardiomyopathy, hepatitis, hypersensitivity reaction (systemic; includes angioedema, dysphagia, dyspnea, pruritus, urticaria), increased serum bilirubin, increased serum transaminases, infertility, injection site reaction (includes injection site cellulitis, local thrombophlebitis, pain at injection site), leukemia (secondary), myocardial infarction, myocarditis, nail bed changes (pigmentation), nail disease (banding), onycholysis, pericarditis, skin rash, sterility, typhlitis (neutropenic)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157101\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to daunorubicin or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Patients who exhibit myocardial lesions or those &ge;75 years of age</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157084\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression:<b> [US Boxed Warning]: May cause severe bone marrow suppression when used at therapeutic doses; may lead to infection or hemorrhage. </b> Use with caution in patients with drug-induced bone marrow suppression (preexisting), unless the therapy benefit outweighs the toxicity risk. Monitor blood counts at baseline and frequently during therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation: <b>[US Boxed Warning]: Potent vesicant; if extravasation occurs, severe local tissue damage leading to ulceration and necrosis, and pain may occur. For IV administration only. NOT for IM or SubQ administration. Administer through a rapidly flowing IV line. </b>Ensure proper needle or catheter placement prior to and during infusion. Avoid extravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal toxicity: Daunorubicin is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting (Dupuis 2011; Hesketh 2017; Roila 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myocardial toxicity: <b>[US Boxed Warning]: May cause cumulative, dose-related myocardial toxicity; may lead to heart failure. May occur either during treatment or may be delayed (months to years after cessations of treatment). The incidence of irreversible myocardial toxicity increases as the total cumulative (lifetime) dosages approach 550 mg/m<sup>2</sup> in adults, 400 mg/m<sup>2</sup> in adults receiving chest radiation, 300 mg/m<sup>2</sup> in children &gt;2 years of age, or 10 mg/kg in children &lt;2 years of age. </b>Total cumulative dose should take into account prior treatment with other anthracyclines or anthracenediones, previous or concomitant treatment with other cardiotoxic agents or irradiation of chest. Although the risk increases with cumulative dose, irreversible cardiotoxicity may occur at any dose level. Patients with preexisting heart disease, hypertension, concurrent administration of other antineoplastic agents, prior or concurrent chest irradiation, advanced age; and infants and children are at increased risk. Monitor left ventricular (LV) function (baseline and periodic) with ECHO or MUGA scan; monitor ECG.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Secondary malignancy: Secondary leukemias may occur when used with combination chemotherapy or radiation therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tumor lysis syndrome: May cause tumor lysis syndrome and hyperuricemia. Urinary alkalinization and prophylaxis with an antihyperuricemic agent may be necessary. Monitor electrolytes, renal function, and hydration status.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment:<b> [US Boxed Warning]: Dosage reductions are recommended in patients with hepatic impairment;</b> significant hepatic impairment may result in increased toxicities.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment:<b> [US Boxed Warning]: Dosage reductions are recommended in patients with renal impairment;</b> significant renal impairment may result in increased toxicities.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Cardiotoxicity may occur more frequently in elderly patients. Use with caution in patients with impaired renal function and/or poor marrow reserve due to advanced age; dosage adjustment may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Infants and children are at increased risk for developing delayed cardiotoxicity; long-term periodic cardiac function monitoring is recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Radiation recipients: Use with caution in patients who have received radiation therapy; reduce dosage in patients who are receiving radiation therapy simultaneously.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Formulations (conventional vs liposomal): Use caution when selecting product for preparation and dispensing; indications, dosages, and adverse event profiles differ between conventional daunorubicin hydrochloride solution and daunorubicin liposomal.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Experienced physician: <b>[US Boxed Warning]: Should be administered under the supervision of an experienced cancer chemotherapy physician.</b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9837877\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of P-glycoprotein/ABCB1</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157089\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9326&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Ado-Trastuzumab Emtansine: May enhance the cardiotoxic effect of Anthracyclines. Management: When possible, patients treated with ado-trastuzumab emtansine should avoid anthracycline-based therapy for up to 7 months after stopping ado-trastuzumab emtansine.  Monitor closely for cardiac dysfunction in patients receiving this combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bevacizumab: May enhance the cardiotoxic effect of Anthracyclines.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: May diminish the cardiotoxic effect of Anthracyclines. Anthracyclines may decrease the serum concentration of Cardiac Glycosides. The effects of liposomal formulations may be unique from those of the free drug, as liposomal formulation have unique drug disposition and toxicity profiles, and liposomes themselves may alter digoxin absorption/distribution.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyclophosphamide: May enhance the cardiotoxic effect of Anthracyclines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumacaftor: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. Lumacaftor may increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Taxane Derivatives: May enhance the adverse/toxic effect of Anthracyclines. Taxane Derivatives may increase the serum concentration of Anthracyclines. Taxane Derivatives may also increase the formation of toxic anthracycline metabolites in heart tissue.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the cardiotoxic effect of Anthracyclines. Management: When possible, patients treated with trastuzumab should avoid anthracycline-based therapy for up to 7 months after stopping trastuzumab.  Monitor closely for cardiac dysfunction in patients receiving anthracyclines with trastuzumab.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157091\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157103\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Daunorubicin crosses the placenta. Women of reproductive potential should avoid pregnancy. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21121942\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if daunorubicin is present into breast milk. Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends a decision be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157093\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential and platelet count, liver function test, ECG, left ventricular ejection function (echocardiography [ECHO] or multigated radionuclide angiography [MUGA] scan), renal function test, signs/symptoms of extravasation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157083\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Daunorubicin inhibits DNA and RNA synthesis by intercalation between DNA base pairs and by steric obstruction. Daunomycin intercalates at points of local uncoiling of the double helix. Although the exact mechanism is unclear, it appears that direct binding to DNA (intercalation) and inhibition of DNA repair (topoisomerase II inhibition) result in blockade of DNA and RNA synthesis and fragmentation of DNA.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157100\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Distributes widely into tissues, particularly the liver, kidneys, lung, spleen, and heart; does not distribute into the CNS</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Primarily hepatic to daunorubicinol (active), then to inactive aglycones, conjugated sulfates, and glucuronides</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Initial: 45 minutes; Terminal: 18.5 hours; Daunorubicinol plasma half-life: ~27 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces (40%); urine (~25% as unchanged drug and metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323094\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Injection</b> (DAUNOrubicin HCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/mL (4 mL): $160.97</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157104\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Cerubidin (AE, BH, CY, DK, EG, FI, GB, HK, IE, IQ, KW, LB, LY, NO, OM, QA, SA, SE, SY, YE);</li>\n      <li>Cerubidine (BE, CH, CL, CZ, FR, LU, NL, NZ, PL, RU, TR, UY);</li>\n      <li>Danocin (BD);</li>\n      <li>Daunobin (IN);</li>\n      <li>Daunoblastin (AT, DE, ZA);</li>\n      <li>Daunoblastina (AE, AR, BH, BR, CN, CY, CZ, EG, ES, GR, HR, HU, IQ, IR, IT, JO, KR, KW, LB, LY, MY, OM, PT, QA, SA, SY, TW, VE, VN, YE);</li>\n      <li>Daunocin (BR, ID, KR, SG, VN);</li>\n      <li>Daunol (UA);</li>\n      <li>Daunoplus (LK);</li>\n      <li>Daunorrubicina (EC, PY);</li>\n      <li>Daunorubicin Injection (AU);</li>\n      <li>Daunorubicina (CU);</li>\n      <li>Daunotec (ET, LK);</li>\n      <li>DaunoXome (FI, LU);</li>\n      <li>Donobin (PK);</li>\n      <li>Maxidauno (AR);</li>\n      <li>Rubicin (BD);</li>\n      <li>Rubilem (CR, DO, GT, HN, MX, NI, PA, PE, SV)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ades L, Sanz MA, Chevret S, et al. Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. <i>Blood</i>. 2008;111(3):1078-1084.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/17975017/pubmed\" target=\"_blank\" id=\"17975017\">17975017</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th Ed. Philadelphia, PA: American College of Physicians, 2007, 98.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cerubidine (daunorubicin) [product monograph]. Montreal, QC: Erfa; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cuttner J, Mick R, Budman DR, et al, &ldquo;Phase III Trial of Brief Intensive Treatment of Adult Acute Lymphocytic Leukemia Comparing Daunorubicin and Mitoxantrone: A CALGB Study,&rdquo; <i>Leukemia</i>, 1991, 5(5):425-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/2033963/pubmed\" target=\"_blank\" id=\"2033963\">2033963</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Daunorubicin (prescribing information). Bedford, OH: Bedford Laboratories; June 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Holdsworth M, et al. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2013;60:1073-1082.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Sung L. Guideline for the Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients. <i>Pediatr Blood Cancer</i>. 2011;57:191-198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/21465637/pubmed\" target=\"_blank\" id=\"21465637\">21465637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. <i>N Engl J Med</i>. 2009;361:1249-1259.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/19776406/pubmed\" target=\"_blank\" id=\"19776406\">19776406</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Floyd J, Mirza I, Sachs B, et al, &ldquo;Hepatotoxicity of Chemotherapy,&rdquo; <i>Semin Oncol</i>, 2006, 33(1):50-67.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/16473644/pubmed\" target=\"_blank\" id=\"16473644\">16473644</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Floyd JD, Nguyen DT, Lobins RL, et al, &ldquo;Cardiotoxicity of Cancer Therapy,&rdquo; <i>J Clin Oncol</i>, 2005, 23(30):7685-96.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/16234530/pubmed\" target=\"_blank\" id=\"16234530\">16234530</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gibson BE, Wheatley K, Hann IM, et al. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. <i>Leukemia</i>. 2005;19(12):2130-2138.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/16304572/pubmed\" target=\"_blank\" id=\"16304572\">16304572</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. <i>J Clin Oncol</i>. 2017;35(28):3240-3261. doi: 10.1200/JCO.2017.74.4789.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/28759346/pubmed\" target=\"_blank\" id=\"28759346\">28759346</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Holowiecki J, Grosicki S, Giebel S, et al. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. <i>J Clin Oncol</i>. 2012;30:2441-2448.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/22508825/pubmed\" target=\"_blank\" id=\"22508825\">22508825</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Huguet F, Lequay T, Raffoux E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. <i>J Clin Oncol</i>. 2009;27:911-918.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/19124805/pubmed\" target=\"_blank\" id=\"19124805\">19124805</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Keefe DL, &ldquo;Anthracycline-Induced Cardiomyopathy,&rdquo; <i>Semin Oncol</i>, 2001, 28(4 Suppl 12):2-7.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Larson RA, Dodge RK, Burns CP, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. <i>Blood</i>. 1995;85:2025-2037.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/7718875/pubmed\" target=\"_blank\" id=\"7718875\">7718875</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Linker C, Damon L, Ries C, et al. Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. <i>J Clin Oncol</i>. 2002;20:2464-2471.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/12011123/pubmed\" target=\"_blank\" id=\"12011123\">12011123</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lowenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. <i>N Engl J Med</i>. 2009;361:1235-1248.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/19776405/pubmed\" target=\"_blank\" id=\"19776405\">19776405</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Masaoka T, Ogawa M, Yamada K, et al, &ldquo;A Phase II Comparative Study of Idarubicin Plus Cytarabine Versus Daunorubicin Plus Cytarabine in Adult Acute Myeloid Leukemia,&rdquo; <i>Semin Hematol</i>, 1996, 33(4 Suppl 3):12-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/8916311/pubmed\" target=\"_blank\" id=\"8916311\">8916311</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Morgan C, Tillett T, Braybrooke J, et al, &ldquo;Management of Uncommon Chemotherapy-Induced Emergencies,&rdquo; <i>Lancet Oncol</i>, 2011, 12(8):806-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/21276754/pubmed\" target=\"_blank\" id=\"21276754\">21276754</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mouridsen HT, Langer SW, Buter J, et al, &ldquo;Treatment of Anthracycline Extravasation With Savene (Dexrazoxane): Results From Two Prospective Clinical Multicentre Studies,&rdquo; <i>Ann Oncol</i>, 2007, 18(3):546-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/17185744/pubmed\" target=\"_blank\" id=\"17185744\">17185744</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nachman JB, La MK, Hunger SP, et al. Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children&rsquo;s oncology group. <i>J Clin Oncol</i>. 2009;27:5189-5194.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/19805689/pubmed\" target=\"_blank\" id=\"19805689\">19805689</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    P&eacute;rez Fidalgo JA, Garc&iacute;a Fabregat L, Cervantes A, et al, &ldquo;Management of Chemotherapy Extravasation: ESMO-EONS Clinical Practice Guidelines,&rdquo; <i>Ann Oncol</i>, 2012, 23(Suppl 7):167-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/22997449/pubmed\" target=\"_blank\" id=\"22997449\">22997449</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Powell BL, Moser B, Stock W, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. <i>Blood</i>. 2010;116:3751-3757.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/20705755/pubmed\" target=\"_blank\" id=\"20705755\">20705755</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ribera JM, Oriol A, Sanz MA, et al. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Espanol de Tratamiento en Hematologia pediatric-based protocol ALL-96. <i>J Clin Oncol</i>. 2008;26:1843-1849.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/18398150/pubmed\" target=\"_blank\" id=\"18398150\">18398150</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roila F, Molassiotis A, Herrstedt J, et al; participants of the MASCC/ESMO Consensus Conference Copenhagen 2015. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. <i>Ann Oncol</i>. 2016;27(suppl 5):v119-v133.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/27664248/pubmed\" target=\"_blank\" id=\"27664248\">27664248</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. <i>Blood</i>. 2005;106:3760-3767.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/16105981/pubmed\" target=\"_blank\" id=\"16105981\">16105981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Speth PA, Minderman H, and Haanen C, &quot;Idarubicin v Daunorubicin: Preclinical and Clinical Pharmacokinetic Studies,&quot; <i>Semin Oncol</i>, 1989, 16(1 Suppl 2):2-9.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weick JK, Kopecky KJ, Appelbaum FR, et al, &ldquo;A Randomized Investigation of High-Dose Versus Standard-Dose Cytosine Arabinoside With Daunorubicin in Patients With Previously Untreated Acute Myeloid Leukemia: A Southwest Oncology Group Study,&rdquo; <i>Blood</i>, 1996, 88(8):2841-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/8874180/pubmed\" target=\"_blank\" id=\"8874180\">8874180</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Woods WG, Kobrinsky N, Buckley JD, et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children&rsquo;s Cancer Group. <i>Blood</i>. 1996;87:4979-4989.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/8652810/pubmed\" target=\"_blank\" id=\"8652810\">8652810</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9326 Version 167.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708684\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F157118\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F157160\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F157121\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F157142\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F157122\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F157123\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F157124\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F157095\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F157080\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F157098\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49130969\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F157096\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F157169\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F157087\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F157101\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F157084\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F9837877\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F157089\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F157091\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F157103\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F21121942\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F157093\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F157083\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F157100\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323094\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F157104\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9326|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=daunorubicin-patient-drug-information\" class=\"drug drug_patient\">Daunorubicin: Patient drug information</a></li><li><a href=\"topic.htm?path=daunorubicin-pediatric-drug-information\" class=\"drug drug_pediatric\">Daunorubicin: Pediatric drug information</a></li></ul></div></div>","javascript":null}